×
模态框（Modal）标题
在这里添加一些文本
Close
Close
Submit
Cancel
Confirm
×
模态框（Modal）标题
在这里添加一些文本
Close
×
Please choose a citation manager
RIS (ProCite, Reference Manager)
BibTeX
Content to export
Citation
Citation and abstract
Export
ISSN 1008-5734
CN 11-4015/R
1999年创刊
主管: 中国科学技术协会
主办: 中华医学会
Toggle navigation
Home
About Journal
Editorial Board
Subscription
Submission
Download
FAQ
Conference
中文
Hot Article
More...
WeChat
Most Read
More...
Most Download
More...
Office
Online Submission
Manuscript Tracking
Editor Work
Office Work
Editor-in-Chief
Journal
Earlier Issues
Current Isue
Advanced Search
Browse by Column
Archive
Most Read
Most Download
Email Alert
RSS
Download
More...
Link
More...
Current Issue
Archive
2025,Vol. 27 No. 4 Published: 28 April 2025
Analysis on the occurrence and influencing factors of adverse drug reactions during long-term therapy with vedolizumab in patients with inflammatory bowel diseases
Xie Dong, Cao Xiaocang, Yuan Hengjie, Li Zhengxiang
2025, 27(4): 193-199.
https://doi.org/10.3760/cma.j.cn114015-20240711-00558
Abstract (
)
PDF
(
)
Literature case analysis of nivolumab-induced Stevens-Johnson syndrome/toxic epidermal necrolysis
Wang Li, Ren Xiuli, Zhang Mei, Lin Zehui, Zhang Xusheng, Lu Cuicui
2025, 27(4): 200-206.
https://doi.org/10.3760/cma.j.cn114015-20240611-00436
Abstract (
)
PDF
(
)
Adverse events in mavacamten treatment for hypertrophic cardiomyopathy: a study based on the US FDA Adverse Event Reporting System database
Yan Yilong, Zhang Yi'nan, Zhao Zhigang
2025, 27(4): 207-211.
https://doi.org/10.3760/cma.j.cn114015-20240620-00473
Abstract (
)
PDF
(
)
Study on risk factors of hypocalcemia in middle and advanced stages of chronic kidney disease patients with hyperkalemia and non-dialysis after potassium lowering therapy
Wang Daoyan, Gao Yanli, Sun Zuoyan, Chen Zhongguang
2025, 27(4): 212-217.
https://doi.org/10.3760/cma.j.cn114015-20250103-00007
Abstract (
)
PDF
(
)
Quality evaluation of adverse drug reaction reports based on weighted TOPSIS-RSR model
Wu Liang, Chen Jingbao, Chen Xiaoxiao, Jiang Shanyue, Shen Yun
2025, 27(4): 218-224.
https://doi.org/10.3760/cma.j.cn114015-20240719-00606
Abstract (
)
PDF
(
)
Safety analysis of different types of influenza vaccines in Fujian Province from 2019 to 2023
Lin Zhiqiang, Xiao Jianxiong, Wu Ruihong, Pan Weiyi, Chen Zhifei, Wang Qin
2025, 27(4): 225-231.
https://doi.org/10.3760/cma.j.cn114015-20240620-00476
Abstract (
)
PDF
(
)
Research progress of biomarkers in immune-related adverse events caused by immune checkpoint inhibitors
Tang Yiheng, Cai Dachuan
2025, 27(4): 232-237.
https://doi.org/10.3760/cma.j.cn114015-20240729-00656
Abstract (
)
PDF
(
)
Research progress on anti-inflammatory mechanism and safety of traditional Chinese medicine in the treatment of epilepsy
Hu Ya'nan, Yue Wei, Ling Ling, Zhang Jinwei
2025, 27(4): 238-244.
https://doi.org/10.3760/cma.j.cn114015-20241109-00140
Abstract (
)
PDF
(
)
Renal insufficiency induced by anaplastic lymphoma kinase inhibitors
Wu Haiting, Wang Hanping, Ye Wei, Li Xuemei, Zheng Ke
2025, 27(4): 245-247.
https://doi.org/10.3760/cma.j.cn 114015-20240711-00533
Abstract (
)
PDF
(
)
Venetoclax-induced tumor lysis syndrome
Guo Ningning, Zhang Yanli
2025, 27(4): 248-251.
https://doi.org/10.3760/cma.j.cn114015-20240918-00050
Abstract (
)
PDF
(
)
Acute kidney injury induced by anti-novel coronavirus drug simnotrelvir/ritonavir
Yu Fuwen, Liu Yubo, Tian Shuxia
2025, 27(4): 251-253.
https://doi.org/10.3760/cma.j.cn114015-20240724-00624
Abstract (
)
PDF
(
)
IgA vasculitis induced by tislelizumab
Wang Kexin, Sun Bao, Luo Zhiying, Que Suyun, Zhang Bikui, Liu Wenhui
2025, 27(4): 253-256.
https://doi.org/10.3760/cma.j.cn114015-20240731-00660
Abstract (
)
PDF
(
)
